- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01771445
Role of Interleukin-1 in the Regulation of Muscle Derived Interleukin-6 During Exercise (MUSIL)
Aim: Evaluate the regulation of muscle derived Interleukin-6 (IL-6)during exercise and in particular whether it is regulated by the Interleukin-1 (IL-1) system.
Rationale: It has been shown that IL-1 antagonism improves glycemia and insulin secretion in patients with type 2 Diabetes. However, IL-1 antagonism also decreases IL-6 levels. The effect if IL-6 on the glucose metabolism has been unclear in the past and subject to intense debate, with recent evidence indicating a beneficial role in regulating glucose metabolism. However little is known about regulation of muscle-induced IL-6 produced during exercise. It is therefore our aim to investigate whether exercise induced increases in IL-6 are dependent on the IL-1 system. If IL-1 antagonism does decrease IL-6 and along with it, the beneficial potential of IL-6, this may require additional medication like IL-6 substitution or dipeptidyl peptidase-IV (DPP-IV)antagonists.
In addition, the investigators will assess the effect of IL-1 antagonism on insulin and Glucagon like peptide-1 (GLP-1) secretion as well as muscle soreness,fatigue and vascular function in response to an acute exercise bout.
Study Overview
Detailed Description
This is a randomized placebo-controlled, double blind, cross-over, proof-of-concept study.
The study will consist of one screening visit followed by 3 study visits. During the first two study visits, the subjects (20 apparently healthy, lean men) will perform a submaximal exercise bout on a treadmill for 60 minutes. Subjects will be randomly assigned into two groups consisting each of 10 subjects receiving study medication in a double-blinded, crossed over manner.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Basel, Switzerland
- University Hospital of Basel, Division of Endocrinology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- male
- non-smoking
- apparently healthy
- BMI > 18 and < 26kg/m2
- Age 20-50 years
- Regular exercise including a minimum of two runs weekly of a total duration of > 2h
- Willingness to use contraceptive measures adequate to prevent the subject's partner from becoming pregnant during the study. Adequate contraceptive measures include hormonal methods used for two or more cycles prior to Screening (e.g., oral contraceptive pills, contraceptive patch, or contraceptive vaginal ring), double barrier methods (e.g., contraceptive sponge, diaphragm used in conjunction with contraceptive foam or jelly, and condom used in conjunction with contraceptive foam or jelly), intrauterine methods (IUD), sterilization (e.g., tubal ligation or a monogamous relationship with a vasectomized partner), and abstinence.
Exclusion Criteria:
- Clinical signs of infection in the week before inclusion or history of infection during the last 3 months (CRP > 5mg/L)
- Impaired fasting glucose (fasting plasma glucose > 5.5mmol/L)
- Hematologic disease (leukocyte count < 1.5x109/L, hemoglobin < 11 g/dL, platelets < 100 x 103/uL)
- Kidney disease (creatinine > 1.5 mg/dL for men and 1.4mg/dL for woman)
- Liver disease (transaminases > 2x upper normal range)
- Heart disease
- Pulmonary disease
- Inflammatory disease
- History of carcinoma
- History of tuberculosis
- Alcohol consumption > 40g/d
- Known allergy to Kineret
- Current treatment with any drug in the week before inclusion, including vitamin supplementation (especially vitamin C and E)
- Use of any investigational drug within 30 days prior to enrollment or within 5 half-lives of the investigational drug, whichever is longer
- Subject refusing or unable to give written informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
100mg, s.c., once only
|
Active Comparator: IL-1Ra
|
100mg, s.c, once only
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
IL6
Time Frame: Change of IL6 during exercise stimulation at baseline compared to change of IL6 during exercise stimulation at day 7
|
Change of IL6 during exercise stimulation at baseline compared to change of IL6 during exercise stimulation at day 7
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
change of inflammatory markers (CRP, Tumor Necrosis Factor alpha, IL-1Ra)
Time Frame: Change of inflammatory markers during exercise stimulation at baseline compared to change of inflammatory markers during exercise stimulation at day 7
|
Change of inflammatory markers during exercise stimulation at baseline compared to change of inflammatory markers during exercise stimulation at day 7
|
Muscle soreness
Time Frame: Change in muscle soreness before and after exercise stimulation at baseline compared to change in muscle soreness before and after exercise stimulation at day 7
|
Change in muscle soreness before and after exercise stimulation at baseline compared to change in muscle soreness before and after exercise stimulation at day 7
|
Activity induced Fatigue (ACTIF) Scale
Time Frame: Change in ACTIF before and after exercise stimulation at baseline compared to change in ACTIF before and after exercise stimulation at day 7
|
Change in ACTIF before and after exercise stimulation at baseline compared to change in ACTIF before and after exercise stimulation at day 7
|
Depression
Time Frame: Change in depression during exercise stimulation at baseline compared to change in depression at day 7
|
Change in depression during exercise stimulation at baseline compared to change in depression at day 7
|
Change of vascular function (CAVI, pulse wave velocity, AVR)
Time Frame: Change in vascular function during exercise stimulation at baseline compared to change of vascular function at day 7
|
Change in vascular function during exercise stimulation at baseline compared to change of vascular function at day 7
|
glucose metabolism
Time Frame: Change glucose metabolism during exercise stimulation at basleine compared to change in glucose metabolism during exercise stimulation at day 7
|
Change glucose metabolism during exercise stimulation at basleine compared to change in glucose metabolism during exercise stimulation at day 7
|
Cognition
Time Frame: Change in cognition during exercise stimulation at baseline compared to change in cognition at day 7
|
Change in cognition during exercise stimulation at baseline compared to change in cognition at day 7
|
Motor strength
Time Frame: Change in motor strength during exercise stimulation at baseline compared to change in motor stength at day 7
|
Change in motor strength during exercise stimulation at baseline compared to change in motor stength at day 7
|
Insulin
Time Frame: Change in insulin during exercise stimulation at baseline compared to change in insulin at day 7
|
Change in insulin during exercise stimulation at baseline compared to change in insulin at day 7
|
Glucagon
Time Frame: Change in glucagon during exercise stimulation at baseline compared to change in glucagon at day 7
|
Change in glucagon during exercise stimulation at baseline compared to change in glucagon at day 7
|
GLP-1
Time Frame: Change in GLP-1 during exercise stimulation at baseline compared to change in GLP-1 at day 7
|
Change in GLP-1 during exercise stimulation at baseline compared to change in GLP-1 at day 7
|
Cortisol
Time Frame: Change in cortisol during exercise stimulation at baseline compared to change in cortisol at day 7
|
Change in cortisol during exercise stimulation at baseline compared to change in cortisol at day 7
|
Creatinkinase
Time Frame: Change in creatinkinase during exercise stimulation at baseline compared to change in creatinkinase at day 7
|
Change in creatinkinase during exercise stimulation at baseline compared to change in creatinkinase at day 7
|
Growth hormone
Time Frame: Change of growth hormone during exercise stimulation at baseline compared to change of growth hormone during exercise stimulation at day 7
|
Change of growth hormone during exercise stimulation at baseline compared to change of growth hormone during exercise stimulation at day 7
|
Copeptin
Time Frame: Change of copeptin during exercise stimulation at baseline compared to change of copeptin during exercise stimulation at day 7
|
Change of copeptin during exercise stimulation at baseline compared to change of copeptin during exercise stimulation at day 7
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marc Y Donath, MD, University of Basel
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MUSIL 294/10
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on IL-1Ra
-
University of ManchesterNorthern Care Alliance NHS Foundation Trust; National Institute for Health... and other collaboratorsActive, not recruiting
-
Mayo ClinicCompletedOsteoarthritis, KneeUnited States
-
Adrian Parry-JonesNorthern Care Alliance NHS Foundation Trust; Manchester University NHS Foundation... and other collaboratorsCompletedIntracerebral HaemorrhageUnited Kingdom
-
Beijing Tongren HospitalChengdu Rhodiola Bio-Pharmaceutical Co LtdUnknownBlepharokeratoconjunctivitisChina
-
Reza Dana, MDCompletedPosterior Blepharitis
-
University of ZurichSteno Diabetes Center CopenhagenCompletedType 2 DiabetesSwitzerland, Denmark
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
Kanuni Sultan Suleyman Training and Research HospitalCompletedGestational DiabetesTurkey
-
Reza Dana, MDTerminatedCorneal NeovascularizationUnited States
-
University of Alabama at BirminghamCompleted